Abbott's ALK-Mutation Companion Dx Finds Home Ahead of Schedule

The recently cleared assay, designed to determine whether a patient with lung cancer has a mutated ALK gene, will be used to identify individuals likely to respond to a Roche drug, Xalkori, which was also recently approved.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.